NASDAQ: SCYXScynexis Inc Stock
$3.82+0.02 (+0.53%)
Updated Jun 23, 2026
SCYX Price
$3.82
Fair Value Price
N/A
Market Cap
$37.93M
52 Week Low
$3.68
52 Week High
$10.48
P/E
-0.99x
P/B
0.92x
P/S
2.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.34M
Earnings
-$24.52M
Gross Margin
100%
Operating Margin
-120.51%
Profit Margin
-120.5%
Debt to Equity
0.88
Operating Cash Flow
-$6M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCYX Overview
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCYX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
SCYX
Ranked#47 of 50
Ranked#47 of 50
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $161.44 | A | |
| $39.96 | A | |
| $82.94 | A |
Be the first to know about important SCYX news, forecast changes, insider trades & much more!
SCYX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCYX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCYX is good value based on its book value relative to its share price (0.92x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.53x)
P/B vs Industry Valuation
SCYX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SCYX due diligence checks available for Premium users.
Valuation
SCYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.99x
Industry
-4.93x
Market
7.68x
SCYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.92x
Industry
1.53x
SCYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCYX's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.3M
Profit Margin
0%
SCYX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SCYX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$77.6M
Liabilities
$36.3M
Debt to equity
0.88
SCYX's short-term assets ($62.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCYX's short-term assets ($62.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCYX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.1M
Investing
-$525.0k
Financing
$24.0M
SCYX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCYX vs Pharmaceutical Stocks
Scynexis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.